RxDoctor Payments Data

Steven Come, MD

Medical Oncology · Boston, MANPI 1619940137

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in MA, where the typical reported total is $2,567.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$420,958in research payments, 2019–2025

Across 22 payments — averaging $19,134 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$363K
  • AstraZeneca$58K

How this compares

$0 in reported general payments places this provider in the 10th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$25,751
Medicare patients
141
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Exemestane11$2,338
Anastrozole44$958
Letrozole37$850
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$730
Lorazepam17$52

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →